IONS
Ionis Pharmaceuticals, Inc.
Price Chart
Latest Quote
$60.36
-0.69 (-1.13%)
Current Price
| Previous Close | $61.05 |
| Open | $60.76 |
| Day High | $60.94 |
| Day Low | $59.70 |
| Volume | 2,017,076 |
Stock Information
| Shares Outstanding | 166.18M |
| Total Debt | $2.19B |
| Cash Equivalents | $2.10B |
| Revenue | $874.09M |
| Net Income | $-565.17M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $10.03B |
| EPS (TTM) | $-3.44 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $10.12B |
| Sales | $874.09M |
| Income | $-565.17M |
| Book/sh | $2.65 |
| Cash/sh | $12.65 |
| Employees | 1K |
Financial Ratios
| Quick Ratio | 6.85 |
| Current Ratio | 7.89 |
| Debt/Eq | 497.80 |
Returns & Margins
| ROA | -12.43% |
| ROE | -105.50% |
| Gross Margin | -6.93% |
| Operating Margin | -38.18% |
| Profit Margin | -64.66% |
Ownership
| Insider Ownership | 0.61% |
| Institutional Ownership | 110.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -55.52 |
| PEG | 27.33 |
| P/S | 11.48 |
| P/B | 22.73 |
Analyst Data
| Recommendation | buy |
| Target Price | $88.00 |
Technical Indicators
| SMA20 | $58.31 |
| SMA50 | $62.88 |
| SMA200 | $73.73 |
| RSI | 59.35 |
| ATR | 1.9579 |
| Shares Float | 164.85M |
| Short Float | 16.66% |
| Short Ratio | 7.02 |
| Volatility | 0.40 |
| Rel Volume | 0.88 |
Performance History
| Week | +1.04% |
| Month | +13.29% |
| Quarter | -21.10% |
| 6 Months | -25.62% |
| YTD | -24.24% |
| Year | +41.19% |
| 3 Years | +51.96% |
| 5 Years | +53.74% |
| 10 Years | +100.93% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-08-31 | $60.36 | 2,017,100 |
| 2026-08-27 | $62.43 | 1,625,200 |
| 2026-08-26 | $63.36 | 2,152,200 |
| 2026-08-25 | $63.57 | 2,432,000 |
| 2026-08-24 | $62.04 | 2,206,900 |
| 2026-08-21 | $59.74 | 2,723,500 |
| 2026-08-20 | $58.76 | 2,124,800 |
| 2026-08-19 | $60.80 | 3,137,600 |
| 2026-08-18 | $59.62 | 3,192,500 |
| 2026-08-17 | $58.63 | 2,000,200 |
| 2026-08-14 | $57.24 | 1,353,700 |
| 2026-08-13 | $55.87 | 1,220,400 |
| 2026-08-12 | $56.53 | 1,999,700 |
| 2026-08-11 | $55.42 | 2,406,900 |
| 2026-08-10 | $56.94 | 2,399,800 |
| 2026-08-07 | $56.56 | 2,009,200 |
| 2026-08-06 | $54.49 | 2,592,300 |
| 2026-08-05 | $54.19 | 2,122,300 |
| 2026-08-04 | $55.07 | 2,688,200 |
| 2026-08-03 | $54.49 | 3,212,600 |
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
đ° Latest News
Could Ionis Pharmaceuticals (IONS) Stock Become a Biotech Powerhouse as its Commercial Pipeline Takes Off?
Insider Monkey âĸ 2026-08-28T22:05:30Z
IONS, AZN Stocks Fall On Full Data From Failed Cardiomyopathy Trial â Jefferies Sees Neutral To Negative Readthrough To ALNY
Stocktwits âĸ 2026-08-28T21:18:55Z
Why Is Ionis Pharmaceuticals (IONS) Up 17.2% Since Last Earnings Report?
Zacks âĸ 2026-08-28T15:30:27Z
Alnylam stock drops on rival heart trial: Why analysts see core business safe
Investing.com âĸ 2026-08-28T12:54:04ZAstraZeneca, Ionis data spark debate about RNA drugsâ impact on deadly heart disease
BioPharma Dive âĸ 2026-08-28T10:58:00Z
Ionis (IONS) Stock Looks Like A Bargain On Value But Full On Sales
Simply Wall St. âĸ 2026-08-16T08:08:19Z
Ionis Pharmaceuticals (IONS) Has A $92 Fair Value Narrative, Is The Stock A Bargain?
Simply Wall St. âĸ 2026-08-15T18:10:59Z
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?
Motley Fool âĸ 2026-08-14T10:35:00Z
Ionis (IONS) Q2 2026 Earnings Call Transcript
Motley Fool âĸ 2026-08-08T00:35:10Z
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?
Motley Fool âĸ 2026-08-03T19:37:01Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $15,909,000 | $11,215,000 | $9,133,000 | $14,116,000 |
| Cost Of Revenue | $15,909,000 | $11,215,000 | $9,133,000 | $14,116,000 |
| Total Revenue | $943,711,000 | $705,138,000 | $787,647,000 | $587,367,000 |
| Operating Revenue | $943,711,000 | $705,138,000 | $787,647,000 | $587,367,000 |
| Expenses | ||||
| Interest Expense | $84,282,000 | $84,357,000 | $81,457,000 | $8,122,000 |
| Total Expenses | $1,325,428,000 | $1,180,245,000 | $1,141,377,000 | $997,558,000 |
| Other Income Expense | $92,627,000 | $105,464,000 | $101,222,000 | $160,328,000 |
| Other Non Operating Income Expenses | $-15,358,000 | $1,331,000 | $14,095,000 | $-7,274,000 |
| Net Non Operating Interest Income Expense | $-90,582,000 | $-90,457,000 | $-81,457,000 | $-8,122,000 |
| Total Other Finance Cost | $6,300,000 | $6,100,000 | $5,900,000 | $5,300,000 |
| Interest Expense Non Operating | $84,282,000 | $84,357,000 | $81,457,000 | $8,122,000 |
| Operating Expense | $1,309,519,000 | $1,169,030,000 | $1,132,244,000 | $983,442,000 |
| General And Administrative Expense | $393,900,000 | $267,500,000 | $232,600,000 | $150,300,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Interest Income | $-90,582,000 | $-90,457,000 | $-81,457,000 | $-8,122,000 |
| Normalized Income | $-466,695,150 | $-556,676,271 | $-435,116,330 | $-402,127,580 |
| Net Income From Continuing And Discontinued Operation | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Total Operating Income As Reported | $-381,684,000 | $-475,081,000 | $-353,730,000 | $-410,191,000 |
| Net Income Common Stockholders | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Income | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Income Including Noncontrolling Interests | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Net Income Continuous Operations | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Pretax Income | $-379,601,000 | $-460,068,000 | $-333,965,000 | $-257,985,000 |
| Operating Income | $-381,717,000 | $-475,107,000 | $-353,730,000 | $-410,191,000 |
| Gross Profit | $927,802,000 | $693,923,000 | $778,514,000 | $573,251,000 |
| Special Income Charges | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 |
| Basic EPS | $-2.38 | $-3.04 | $-2.56 | $-1.90 |
| Other | ||||
| Tax Effect Of Unusual Items | $22,676,850 | $1,353,729 | $18,296,670 | $35,196,420 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-380,610,000 | $-457,854,000 | $-317,137,000 | $-395,360,000 |
| Total Unusual Items | $107,985,000 | $104,133,000 | $87,127,000 | $167,602,000 |
| Total Unusual Items Excluding Goodwill | $107,985,000 | $104,133,000 | $87,127,000 | $167,602,000 |
| Reconciled Depreciation | $22,694,000 | $21,990,000 | $22,498,000 | $22,105,000 |
| EBITDA (Bullshit earnings) | $-272,625,000 | $-353,721,000 | $-230,010,000 | $-227,758,000 |
| EBIT | $-295,319,000 | $-375,711,000 | $-252,508,000 | $-249,863,000 |
| Diluted Average Shares | $160,000,000 | $150,000,000 | $143,000,000 | $142,000,000 |
| Basic Average Shares | $160,000,000 | $150,000,000 | $143,000,000 | $142,000,000 |
| Diluted NI Availto Com Stockholders | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Tax Provision | $1,786,000 | $-6,171,000 | $32,321,000 | $11,737,000 |
| Gain On Sale Of Security | $107,985,000 | $104,133,000 | $87,127,000 | $167,602,000 |
| Research And Development | $915,619,000 | $901,530,000 | $899,625,000 | $833,147,000 |
| Selling General And Administration | $393,900,000 | $267,500,000 | $232,619,000 | $150,295,000 |
| Other Gand A | $352,000,000 | $230,500,000 | $205,100,000 | $124,400,000 |
| Salaries And Wages | $41,900,000 | $37,000,000 | $27,500,000 | $25,900,000 |
| Minority Interests | - | - | - | $0 |
| Restructuring And Mergern Acquisition | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-08-29
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Total Assets | $3,523,836,000 | $3,003,675,000 | $2,990,072,000 | $2,533,876,000 |
| Total Non Current Assets | $533,201,000 | $383,385,000 | $348,219,000 | $331,182,000 |
| Other Non Current Assets | $171,604,000 | $127,278,000 | $105,280,000 | $75,344,000 |
| Current Assets | $2,990,635,000 | $2,620,290,000 | $2,641,853,000 | $2,202,694,000 |
| Other Current Assets | $237,092,000 | $217,934,000 | $205,433,000 | $168,254,000 |
| Inventory | $10,048,000 | $12,512,000 | $7,441,000 | $22,033,000 |
| Receivables | $66,059,000 | $92,188,000 | $97,778,000 | $25,538,000 |
| Other Receivables | $66,059,000 | $92,188,000 | $97,778,000 | $25,538,000 |
| Cash Cash Equivalents And Short Term Investments | $2,677,436,000 | $2,297,656,000 | $2,331,201,000 | $1,986,869,000 |
| Cash And Cash Equivalents | $372,260,000 | $242,077,000 | $399,266,000 | $276,472,000 |
| Non Current Prepaid Assets | - | - | - | - |
| Goodwill And Other Intangible Assets | - | - | - | - |
| Other Intangible Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,429,869,000 | $1,012,687,000 | $883,398,000 | $913,782,000 |
| Total Debt | $2,064,512,000 | $1,416,569,000 | $1,453,539,000 | $1,369,195,000 |
| Long Term Debt And Capital Lease Obligation | $1,609,826,000 | $1,407,290,000 | $1,400,376,000 | $1,361,660,000 |
| Long Term Debt | $1,347,443,000 | $1,245,485,000 | $1,229,501,000 | $1,182,719,000 |
| Current Debt And Capital Lease Obligation | $454,686,000 | $9,279,000 | $53,163,000 | $7,535,000 |
| Current Debt | $454,686,000 | $9,279,000 | $53,163,000 | $7,535,000 |
| Other Current Borrowings | $454,686,000 | $9,279,000 | $53,163,000 | $7,535,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $3,034,747,000 | $2,415,324,000 | $2,603,386,000 | $1,960,989,000 |
| Total Non Current Liabilities Net Minority Interest | $2,253,180,000 | $2,106,006,000 | $2,155,296,000 | $1,649,428,000 |
| Other Non Current Liabilities | $551,353,000 | $542,212,000 | $513,736,000 | - |
| Non Current Deferred Liabilities | $92,001,000 | $156,504,000 | $241,184,000 | $287,768,000 |
| Current Liabilities | $781,567,000 | $309,318,000 | $448,090,000 | $311,561,000 |
| Current Deferred Liabilities | $73,761,000 | $78,989,000 | $151,128,000 | $90,577,000 |
| Payables And Accrued Expenses | $136,884,000 | $151,436,000 | $176,072,000 | $164,271,000 |
| Payables | $30,795,000 | $42,998,000 | $28,178,000 | $24,170,000 |
| Total Tax Payable | $2,713,000 | $34,000 | $2,151,000 | $6,249,000 |
| Income Tax Payable | $2,713,000 | $34,000 | $2,151,000 | $6,249,000 |
| Accounts Payable | $28,082,000 | $42,964,000 | $26,027,000 | $17,921,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Total Equity Gross Minority Interest | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Stockholders Equity | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Gains Losses Not Affecting Retained Earnings | $-25,281,000 | $-30,811,000 | $-32,645,000 | $-57,480,000 |
| Other Equity Adjustments | $-25,281,000 | $-30,811,000 | $-32,645,000 | $-57,480,000 |
| Retained Earnings | $-2,631,195,000 | $-2,249,808,000 | $-1,795,911,000 | $-1,429,625,000 |
| Other | ||||
| Ordinary Shares Number | $163,304,875 | $157,908,815 | $144,340,526 | $142,057,736 |
| Share Issued | $163,304,875 | $157,908,815 | $144,340,526 | $142,057,736 |
| Tangible Book Value | $489,089,000 | $588,351,000 | $386,686,000 | $572,887,000 |
| Invested Capital | $2,291,218,000 | $1,843,115,000 | $1,669,350,000 | $1,763,141,000 |
| Working Capital | $2,209,068,000 | $2,310,972,000 | $2,193,763,000 | $1,891,133,000 |
| Capital Lease Obligations | $262,383,000 | $161,805,000 | $170,875,000 | $178,941,000 |
| Total Capitalization | $1,836,532,000 | $1,833,836,000 | $1,616,187,000 | $1,755,606,000 |
| Additional Paid In Capital | $3,145,402,000 | $2,868,812,000 | $2,215,098,000 | $2,059,850,000 |
| Capital Stock | $163,000 | $158,000 | $144,000 | $142,000 |
| Common Stock | $163,000 | $158,000 | $144,000 | $142,000 |
| Non Current Deferred Revenue | $92,001,000 | $156,504,000 | $241,184,000 | $287,768,000 |
| Long Term Capital Lease Obligation | $262,383,000 | $161,805,000 | $170,875,000 | $178,941,000 |
| Current Deferred Revenue | $73,761,000 | $78,989,000 | $151,128,000 | $90,577,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $116,236,000 | $69,614,000 | $67,727,000 | $49,178,000 |
| Current Accrued Expenses | $106,089,000 | $108,438,000 | $147,894,000 | $140,101,000 |
| Net PPE | $361,597,000 | $256,107,000 | $242,939,000 | $255,838,000 |
| Accumulated Depreciation | $-109,080,000 | $-106,316,000 | $-96,759,000 | $-87,716,000 |
| Gross PPE | $470,677,000 | $362,423,000 | $339,698,000 | $343,554,000 |
| Leases | $89,153,000 | $54,375,000 | $28,276,000 | $28,357,000 |
| Other Properties | $238,549,000 | $161,856,000 | $171,896,000 | $181,544,000 |
| Machinery Furniture Equipment | $101,174,000 | $96,395,000 | $89,729,000 | $83,926,000 |
| Buildings And Improvements | $41,801,000 | $41,228,000 | $41,228,000 | $41,158,000 |
| Land And Improvements | $0 | $8,569,000 | $8,569,000 | $8,569,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,096,000 | $276,000 | $154,000 | $164,000 |
| Work In Process | $7,913,000 | $6,679,000 | $5,477,000 | $2,109,000 |
| Raw Materials | $1,039,000 | $5,557,000 | $1,810,000 | $19,760,000 |
| Other Short Term Investments | $2,305,176,000 | $2,055,579,000 | $1,931,935,000 | $1,710,397,000 |
Fetched: 2026-08-29
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-325,667,000 | $-551,288,000 | $-335,502,000 | $-294,469,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-268,583,000 | $-500,947,000 | $-307,513,000 | $-274,370,000 |
| Cash Flow From Continuing Operating Activities | $-268,583,000 | $-500,947,000 | $-307,513,000 | $-274,370,000 |
| Operating Gains Losses | $4,059,000 | $13,328,000 | $6,671,000 | $-147,350,000 |
| Investing Activities | ||||
| Capital Expenditure | $-57,084,000 | $-50,341,000 | $-27,989,000 | $-20,099,000 |
| Investing Cash Flow | $-277,776,000 | $-134,027,000 | $-214,127,000 | $-262,636,000 |
| Cash Flow From Continuing Investing Activities | $-277,776,000 | $-134,027,000 | $-214,127,000 | $-262,636,000 |
| Net Other Investing Changes | - | - | $22,000 | $254,083,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $192,604,000 | $522,729,000 | $49,442,000 | $6,373,000 |
| Financing Cash Flow | $675,840,000 | $478,058,000 | $644,082,000 | $-55,295,000 |
| Cash Flow From Continuing Financing Activities | $675,840,000 | $478,058,000 | $644,082,000 | $-55,295,000 |
| Net Other Financing Charges | $-18,949,000 | - | $507,743,000 | $-10,982,000 |
| Net Common Stock Issuance | $192,604,000 | $522,729,000 | $49,442,000 | $6,373,000 |
| Common Stock Issuance | $192,604,000 | $522,729,000 | $49,442,000 | $6,373,000 |
| Repurchase Of Capital Stock | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-267,815,000 | $-44,671,000 | $-488,103,000 | $-50,686,000 |
| Issuance Of Debt | $770,000,000 | $0 | $575,000,000 | $0 |
| Interest Paid Supplemental Data | $10,782,000 | $10,869,000 | $6,512,000 | $2,898,000 |
| End Cash Position | $372,260,000 | $242,077,000 | $399,266,000 | $276,472,000 |
| Beginning Cash Position | $242,077,000 | $399,266,000 | $276,472,000 | $869,191,000 |
| Effect Of Exchange Rate Changes | $702,000 | $-273,000 | $352,000 | $-418,000 |
| Changes In Cash | $129,481,000 | $-156,916,000 | $122,442,000 | $-592,301,000 |
| Net Issuance Payments Of Debt | $502,185,000 | $-44,671,000 | $86,897,000 | $-50,686,000 |
| Net Short Term Debt Issuance | $0 | $-44,504,000 | $-487,943,000 | $0 |
| Short Term Debt Payments | $0 | $-44,504,000 | $-487,943,000 | $0 |
| Net Long Term Debt Issuance | $502,185,000 | $-167,000 | $574,840,000 | $-50,686,000 |
| Long Term Debt Payments | $-267,815,000 | $-167,000 | $-160,000 | $-50,686,000 |
| Long Term Debt Issuance | $770,000,000 | $0 | $575,000,000 | $0 |
| Net Investment Purchase And Sale | $-220,692,000 | $-83,686,000 | $-186,138,000 | $-496,620,000 |
| Sale Of Investment | $1,697,870,000 | $1,769,172,000 | $1,584,676,000 | $989,152,000 |
| Purchase Of Investment | $-1,918,562,000 | $-1,852,858,000 | $-1,770,814,000 | $-1,485,772,000 |
| Net Intangibles Purchase And Sale | $-5,640,000 | $-5,061,000 | $-4,184,000 | $-4,378,000 |
| Purchase Of Intangibles | $-5,640,000 | $-5,061,000 | $-4,184,000 | $-4,378,000 |
| Net PPE Purchase And Sale | $-51,444,000 | $-45,280,000 | $-23,805,000 | $-15,721,000 |
| Purchase Of PPE | $-51,444,000 | $-45,280,000 | $-23,805,000 | $-15,721,000 |
| Change In Working Capital | $-51,215,000 | $-209,390,000 | $-77,260,000 | $7,571,000 |
| Change In Other Working Capital | $-67,052,000 | $-158,936,000 | $9,869,000 | $-65,035,000 |
| Change In Other Current Assets | $-33,212,000 | $-25,857,000 | $-33,763,000 | $-27,235,000 |
| Change In Payables And Accrued Expense | $36,594,000 | $-25,116,000 | $21,162,000 | $58,157,000 |
| Change In Accrued Expense | $51,954,000 | $-41,106,000 | $13,043,000 | $57,063,000 |
| Change In Payable | $-15,360,000 | $15,990,000 | $8,119,000 | $1,094,000 |
| Change In Account Payable | $-15,360,000 | $15,990,000 | $8,119,000 | $1,094,000 |
| Change In Inventory | $-13,674,000 | $-5,071,000 | $-2,469,000 | $5,326,000 |
| Change In Receivables | $26,129,000 | $5,590,000 | $-72,059,000 | $36,358,000 |
| Other Non Cash Items | $27,127,000 | $34,555,000 | $29,940,000 | $5,373,000 |
| Stock Based Compensation | $133,874,000 | $130,200,000 | $105,809,000 | $100,264,000 |
| Amortization Of Securities | $-23,735,000 | $-37,733,000 | $-28,885,000 | $7,389,000 |
| Depreciation Amortization Depletion | $22,694,000 | $21,990,000 | $22,498,000 | $22,105,000 |
| Depreciation And Amortization | $22,694,000 | $21,990,000 | $22,498,000 | $22,105,000 |
| Amortization Cash Flow | $2,439,000 | $2,336,000 | $2,559,000 | $2,415,000 |
| Amortization Of Intangibles | $2,439,000 | $2,336,000 | $2,559,000 | $2,415,000 |
| Depreciation | $20,255,000 | $19,654,000 | $19,939,000 | $19,690,000 |
| Gain Loss On Investment Securities | $-9,280,000 | $2,892,000 | $1,589,000 | $-149,911,000 |
| Gain Loss On Sale Of PPE | $-3,991,000 | $7,404,000 | $16,649,000 | $531,000 |
| Net Income From Continuing Operations | $-381,387,000 | $-453,897,000 | $-366,286,000 | $-269,722,000 |
| Income Tax Paid Supplemental Data | - | - | $48,334,000 | $5,010,000 |
| Proceeds From Stock Option Exercised | - | - | $0 | $0 |
| Common Stock Payments | - | - | - | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
Fetched: 2026-08-29